Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors

2020 ◽  
Vol 20 (9) ◽  
pp. 755-763 ◽  
Author(s):  
Veronica Mollica ◽  
Ilaria Maggio ◽  
Antonio Lopez-Beltran ◽  
Rodolfo Montironi ◽  
Alessia Cimadamore ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Urothelial Cancer ◽  
Mtor Inhibitors ◽  
Her 2 ◽  
Advanced Urothelial Cancer

scholarly journals Incorporating VEGF-targeted therapy in advanced urothelial cancer

2016 ◽  
Vol 9 (1) ◽  
pp. 33-45 ◽  
Author(s):  
Sujata Narayanan ◽  
Sandy Srinivas
Keyword(s):  
Poor Prognosis ◽  
Urothelial Cancer ◽  
Systemic Treatment ◽  
Angiogenesis Inhibitors ◽  
Chemotherapeutic Agents ◽  
Second Line ◽  
Targeted Agents ◽  
Predictors Of Response ◽  
Advanced Urothelial Cancer

Patients with relapsed or refractory urothelial carcinoma (UC) have poor prognosis coupled with few options for systemic treatment. The role of angiogenesis in the evolution of cancers has been established, and studies have shown that it plays a key role in the pathogenesis of UC. Many targeted agents have been used in phase I–II trials for the treatment of UC, with encouraging but modest results. Recently, studies combining angiogenesis inhibitors with other chemotherapeutic agents were able to achieve objective responses higher than most commonly used second-line therapies in UC. Future efforts in investigating these therapies in UC rely on identification of biomarkers and other predictors of response to anti-VEGF therapy.

Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio

2018 ◽  
Vol 16 (3) ◽  
pp. e637-e644 ◽  
Author(s):  
Steven M. Yip ◽  
Jeenan Kaiser ◽  
Haocheng Li ◽  
Scott North ◽  
Daniel Y.C. Heng ◽  
...  
Keyword(s):  
Real World ◽  
Urothelial Cancer ◽  
Neutrophil To Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Advanced Urothelial Cancer
Sign in / Sign up

Export Citation Format

Share Document